GBM Autoantibody, Quantitative

Test Name
GBM Autoantibody, Quantitative
Aliases
Anti-GBM; Glomerular Basement Memberane Autoantibody
Provincial Mnemonic
GLBMAB
LOINC Test Code
59394-7
Description and Primary Use
Quantitative GBM autoantibody referred out testing is only performed when the qualitative test of the GVDS panel have reported positivity for the GBM autoantibody. The diagnosis of Goodpasture’s disease relies on the detection of GBM autoantibodies in tissues or circulation in combination with the detection of glomerulonephritis and/or alveolitis. GBM autoantibodies are highly specific and sensitive markers of the disease and are by definition present in all patients with Goodpasture’s disease. Clinical progression of the disease correlates with antibody concentrations, with high concentrations of circulating GBM autoantibodies indicating an unfavorable prognosis.
Reorder interval
30d
TAT
14 Days; max delay 31 days.
Test Cost
Not Available
Tier
2 - Conditional/Restricted Access (See Ordering Requirements)
Ordering Requirements (Restrictions / Conditions)

Quantitative GBM autoantibody is only performed when the qualitative test of the GVDS panel have reported positivity for the GBM autoantibody.

Approval requires:

  • Ordered by Rheumatology
  • Completed LTSA Form.

Enter test name (and/or Provincial Mnemonic) into Test(s) to be performed section on the LTSA Form. Direct questions on how to order test to Specimen Dispatch (709-777-2373).

Required Consultations
Algorithms and Guidelines
Special Patient Preparation

None

Special Collection / Transport / Processing Requirements

No special requirement

Criteria for Rejection

Please consult specimen stability guide

Laboratory Service Area
Clinical Chemistry
Performing Laboratory / Site
Category 4 Laboratory (HSC only)
Last Updated
04-Sep-19